|
* Market Opportunity: Breast Cancer > $20B, 20m Mammograms/year in US, 15% result in "call backs"
* Technology: Non-invasive saliva testing * Management Team: Life Sciences Veterans. Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics |
Market Opportunity: Breast cancer screening is the largest established cancer screening market at over $20B with over 40m mammograms performed annually in the US. But mammography can be uncomfortable, embarrassing, and subject to ambiguous results. For annual screening mammograms, 15% result in “call backs” from ambiguous and inconclusive images. This leaves patients with expensive and invasive workups to obtain more definitive diagnosis including ultrasounds, MRI and surgical biopsy.
Technology: The company has developed a breast cancer screening platform using non-invasive saliva sampling and gene expression profiles to be used as a complement for call backs. Their test is performed as a secondary screen upon a call back on an ambiguous screening mammogram.
Management Team: The company is led by successful life sciences industry veterans with extensive experience building multi-million dollar molecular diagnostics and DNA/RNA technology companies, including Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics. The board is comprised of visionary diagnostics investors (who've returned over $2B in capital to investors) and world leading experts in commercialization of genomics technologies. The scientific advisory board includes academic thought leaders at Stanford, UCSF, UCSC, Tufts and the Univ. of Virginia.
Given the elegance of sample collection, simple assay, results to date and experience of the management team, the company is poised to develop a capitally-efficient, results-driven business capable of fundamentally improving breast cancer screening programs. Further, this approach will be of broad interest to the industry, offering strategic partnership and M&A opportunities.
Michele Colucci is Chairman of the Board
Technology: The company has developed a breast cancer screening platform using non-invasive saliva sampling and gene expression profiles to be used as a complement for call backs. Their test is performed as a secondary screen upon a call back on an ambiguous screening mammogram.
Management Team: The company is led by successful life sciences industry veterans with extensive experience building multi-million dollar molecular diagnostics and DNA/RNA technology companies, including Artemis/Verinata, Amersham/GE Healthcare, Centrillion, Siemens, and Affymetrix/Panomics. The board is comprised of visionary diagnostics investors (who've returned over $2B in capital to investors) and world leading experts in commercialization of genomics technologies. The scientific advisory board includes academic thought leaders at Stanford, UCSF, UCSC, Tufts and the Univ. of Virginia.
Given the elegance of sample collection, simple assay, results to date and experience of the management team, the company is poised to develop a capitally-efficient, results-driven business capable of fundamentally improving breast cancer screening programs. Further, this approach will be of broad interest to the industry, offering strategic partnership and M&A opportunities.
Michele Colucci is Chairman of the Board
